0001326110-21-000009 | 10-Q | XBRL Viewer

Label	Element	Value
Available For Sale Securities Debt Securities Period	ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod	1 month 6 days
Available For Sale Securities Debt Securities Period	ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod	6 months
Available For Sale Securities Debt Securities Period	ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod	5 years 1 month 6 days
Prepaid Services	ibrx_PrepaidServices	$ 2,373,000
Prepaid Services	ibrx_PrepaidServices	1,294,000
Accrued Dissenting Shares	ibrx_AccruedDissentingShares	7,029,000
Accrued Dissenting Shares	ibrx_AccruedDissentingShares	6,769,000
Insurance Premium Financing Asset	ibrx_InsurancePremiumFinancingAsset	4,137,000
Insurance Premium Financing Asset	ibrx_InsurancePremiumFinancingAsset	1,421,000
Prepaid Insurance In Other Assets	ibrx_PrepaidInsuranceInOtherAssets	3,042,000
Prepaid Insurance In Other Assets	ibrx_PrepaidInsuranceInOtherAssets	0
Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets	ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets	1,549,000
Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets	ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets	92,000
Prepaid Equipment Maintenance	ibrx_PrepaidEquipmentMaintenance	229,000
Prepaid Equipment Maintenance	ibrx_PrepaidEquipmentMaintenance	243,000
Base Monthly Rent	ibrx_BaseMonthlyRent	47,000
Base Monthly Rent	ibrx_BaseMonthlyRent	54,500
Base Monthly Rent	ibrx_BaseMonthlyRent	72,385
Base Monthly Rent	ibrx_BaseMonthlyRent	40,700
Base Monthly Rent	ibrx_BaseMonthlyRent	35,800
Base Monthly Rent	ibrx_BaseMonthlyRent	20,300
Base Monthly Rent	ibrx_BaseMonthlyRent	170,400
Base Monthly Rent	ibrx_BaseMonthlyRent	81,976
Base Monthly Rent	ibrx_BaseMonthlyRent	$ 38,250
Issuance Of Common Stock Under At Market Offering Shares	ibrx_IssuanceOfCommonStockUnderAtMarketOfferingShares	10,216,978
Prepaid License Fees	ibrx_PrepaidLicenseFees	$ 1,377,000
Prepaid License Fees	ibrx_PrepaidLicenseFees	801,000
Common Stock Value Available For Future Stock Issuance	ibrx_CommonStockValueAvailableForFutureStockIssuance	359,000,000
Accrued Preclinical And Clinical Trial Costs	ibrx_AccruedPreclinicalAndClinicalTrialCosts	5,426,000
Accrued Preclinical And Clinical Trial Costs	ibrx_AccruedPreclinicalAndClinicalTrialCosts	4,339,000
Related Party, Cash Paid For Interest	ibrx_RelatedPartyCashPaidForInterest	1,400,000
Business Combination, Contingent Consideration Arrangements, Earned	ibrx_BusinessCombinationContingentConsiderationArrangementsEarned	800,000
Prepaid Property Taxes	ibrx_PrepaidPropertyTaxes	373,000
Prepaid Property Taxes	ibrx_PrepaidPropertyTaxes	0
Business Combination, Contingent Consideration Arrangements, Settlements	ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements	400,000
E R P System Implementation Costs In Other Assets	ibrx_ERPSystemImplementationCostsInOtherAssets	729,000
E R P System Implementation Costs In Other Assets	ibrx_ERPSystemImplementationCostsInOtherAssets	0
Contingent Value Rights Payable	ibrx_ContingentValueRightsPayable	304,000,000
Contingent Value Rights Payable	ibrx_ContingentValueRightsPayable	304,000,000
Contingent Value Rights Payable	ibrx_ContingentValueRightsPayable	279,500,000
Related Party, Installment Payment	ibrx_RelatedPartyInstallmentPayment	3,800,000
Related Party, Installment Payment	ibrx_RelatedPartyInstallmentPayment	$ 1,900,000
Merger Exchange Ratio	ibrx_MergerExchangeRatio	0.8190
Merger Exchange Ratio	ibrx_MergerExchangeRatio	0.8190
Operating Lease Right Of Use Asset Non Cash Lease Expense	ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense	$ 3,500,000
Operating Lease Right Of Use Asset Non Cash Lease Expense	ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense	3,374,000
Minimum Net Sales Milestone Contingent Value Rights Payable	ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable	1,000,000,000
Non Cash Interest Income Expense From Operating Activities	ibrx_NonCashInterestIncomeExpenseFromOperatingActivities	(9,126,000)
Non Cash Interest Income Expense From Operating Activities	ibrx_NonCashInterestIncomeExpenseFromOperatingActivities	(5,743,000)
Accrued Payment For Dissenting Shares	ibrx_AccruedPaymentForDissentingShares	7,000,000
Accrued Payment For Dissenting Shares	ibrx_AccruedPaymentForDissentingShares	6,800,000
Prepaid Expenses And Other Current Assets Reclassified	ibrx_PrepaidExpensesAndOtherCurrentAssetsReclassified	800,000
Equipment Deposits Current	ibrx_EquipmentDepositsCurrent	0
Equipment Deposits Current	ibrx_EquipmentDepositsCurrent	66,000
Prepaid Software License Fees In Other Assets	ibrx_PrepaidSoftwareLicenseFeesInOtherAssets	132,000
Prepaid Software License Fees In Other Assets	ibrx_PrepaidSoftwareLicenseFeesInOtherAssets	455,000
Aggregate Market Price Of Shares That May Issue Under Registered Offering	ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering	500,000,000
Accrued Research And Development Costs	ibrx_AccruedResearchAndDevelopmentCosts	3,871,000
Accrued Research And Development Costs	ibrx_AccruedResearchAndDevelopmentCosts	4,002,000
Prepaid Preclinical And Clinical Trial Services With Related Party	ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty	1,035,000
Prepaid Preclinical And Clinical Trial Services With Related Party	ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty	4,626,000
Accrued Capital Expenditures	ibrx_AccruedCapitalExpenditures	1,585,000
Accrued Capital Expenditures	ibrx_AccruedCapitalExpenditures	337,000
Related Party Transaction Conditional Payment	ibrx_RelatedPartyTransactionConditionalPayment	1,900,000
Related Party Transaction Conditional Payment	ibrx_RelatedPartyTransactionConditionalPayment	1,900,000
Accrued Laboratory Equipment Supplies And Related Services	ibrx_AccruedLaboratoryEquipmentSuppliesAndRelatedServices	801,000
Accrued Laboratory Equipment Supplies And Related Services	ibrx_AccruedLaboratoryEquipmentSuppliesAndRelatedServices	641,000
Operating Lease Payments Related To Options To Extend Lease Terms	ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms	$ 21,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Vesting Installments	ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfVestingInstallments	3
Number Of Awards Granted	ibrx_NumberOfAwardsGranted	2
Sale-leaseback Transaction, Consideration Transferred	ibrx_SaleLeasebackTransactionConsiderationTransferred	$ 22,000,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	55,226,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	50,000,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	40,000,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	55,000,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	43,418,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	33,000,000
Related Party Notes Payable	ibrx_RelatedPartyNotesPayable	276,644,000
Sale-leaseback Transaction, Property Taxes	ibrx_SaleLeasebackTransactionPropertyTaxes	100,000
Lessee, Operating Lease, Liability, to be Paid, Due after Year Four	ibrx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	28,144,000
Lessee, Operating Lease, Liability, Tenant Improvement Allowance Receivable	ibrx_LesseeOperatingLeaseLiabilityTenantImprovementAllowanceReceivable	$ 2,941,000
Modified Options Exercisable Period	ibrx_ModifiedOptionsExercisablePeriod	90 days
Period Of Rent Free Lease Term	ibrx_PeriodOfRentFreeLeaseTerm	2 years
Prepayment Of Funding Amount	ibrx_PrepaymentOfFundingAmount	$ 600,000
Rent Abatement Period	ibrx_RentAbatementPeriod	7 months
Rent Abatement Period	ibrx_RentAbatementPeriod	7 months
Lessee, Operating Lease, Prepaid Expense	ibrx_LesseeOperatingLeasePrepaidExpense	$ 200,000
Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value	ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue	$ 4,000,000
Number Of Board Of Directors Resignation	ibrx_NumberOfBoardOfDirectorsResignation	2
Prepaid Supplies With Related Party	ibrx_PrepaidSuppliesWithRelatedParty	$ 0
Prepaid Supplies With Related Party	ibrx_PrepaidSuppliesWithRelatedParty	143,000
Increase Decrease In Due To Related Parties Current And Non Current	ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	(4,714,000)
Increase Decrease In Due To Related Parties Current And Non Current	ibrx_IncreaseDecreaseInDueToRelatedPartiesCurrentAndNonCurrent	4,727,000
Leasehold Improvement Payables	ibrx_LeaseholdImprovementPayables	900,000
Leasehold Improvement Payables	ibrx_LeaseholdImprovementPayables	700,000
Convertible Note Receivable Non Current	ibrx_ConvertibleNoteReceivableNonCurrent	6,316,000
Convertible Note Receivable Non Current	ibrx_ConvertibleNoteReceivableNonCurrent	6,129,000
Lease Related Payables	ibrx_LeaseRelatedPayables	300,000
Lease Related Payables	ibrx_LeaseRelatedPayables	$ 1,100,000

Collaboration and License Agreements - Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Millions			1 Months Ended			9 Months Ended		12 Months Ended
	Nov. 12, 2021	Feb. 22, 2021	Sep. 30, 2021	Feb. 28, 2018	Jan. 31, 2018	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Research and Development Arrangements with Federal Government [Line Items]
Annual payment for support of research activities		$ 0.1	$ 2.0	$ 0.2	$ 0.6
Payment for support of research activities						$ 0.1	$ 0.5
Annual project funding amount	$ 1.3
Payable related for support of research activities, additional	$ 0.7
Estimated unpaid research and development expense						$ 0.5		$ 0.6

Collaboration and License Agreements - License Agreements - Additional Information (Detail) - USD ($)		1 Months Ended				9 Months Ended
	Feb. 22, 2021	Sep. 30, 2021	May 31, 2021	Feb. 28, 2018	Jan. 31, 2018	Sep. 30, 2021	Dec. 31, 2020
Licensing Agreement [Line Items]
Non-refundable upfront cash payments		$ 1,500,000	$ 2,000,000			$ 2,000,000
Milestone payment, payable amount			$ 2,500,000
Milestone fees						0
Termination fee		10,000,000				10,000,000
Milestone payment, amount		4,000,000				4,000,000
Annual payment for support of research activities	$ 100,000	2,000,000		$ 200,000	$ 600,000
Accrued reimbursable costs payable		200,000				200,000	$ 500,000
2022
Licensing Agreement [Line Items]
License maintenance fees		3,000,000				3,000,000
2023 through 2030
Licensing Agreement [Line Items]
License maintenance fees		$ 5,500,000				$ 5,500,000

Financial Statement Details - Additional Information (Detail) $ in Millions						1 Months Ended
	Oct. 01, 2021 Term	Apr. 01, 2021	Jan. 01, 2021	Jan. 01, 2021 option	Jan. 01, 2021 Term	Sep. 30, 2021 option	Jan. 31, 2019 Term	Aug. 31, 2018	Feb. 28, 2017 Term	Sep. 30, 2016 Term	Sep. 27, 2021 USD ($)
Financial Statement Details [Line Items]
Options to extend number of terms	2			1	1	2	2		2	1
Optional extended lease term	5 years	3 years	3 years			7 years	5 years	1 year	5 years	3 years
Sale leaseback transaction, net proceeds											$ 21.9

Print Document View Excel Document
Notes Details Financial Statement Details - Additional Information (Detail) Collaboration and License Agreements - Collaboration Agreements - Additional Information (Detail) Collaboration and License Agreements - License Agreements - Additional Information (Detail) Uncategorized Uncategorized Items - ibrx-20210930_htm.xml All Reports